Vasudev Jaiprakash Bailey - 28 May 2026 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Director
Issuer ticker: RANI
Reported as of: 28 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2026, 16:09:07 UTC
Prior SEC filing: 30 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Svai Sanford, Attorney-in-Fact

Key filing fact

Vasudev Jaiprakash Bailey filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 01 Jun 2026.

Key facts

This page summarizes Vasudev Jaiprakash Bailey's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Jun 2026, 16:09.

Change

Previous filing in this sequence was filed on 30 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002094741 Primary reporting owner

Bailey Vasudev Jaiprakash

Relationship: Director
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE, SAN JOSE
Signature: /s/ Svai Sanford, Attorney-in-Fact
Signature date: 01 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RANI transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
Shares: +123,600
Change %
Price: $0.000000^*
Shares after: 123,600
Date: 28 May 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 123,600
Exercise price: $0.9515
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.